Brodalumab for psoriasis eases symptoms, ups treatment satisfaction

In the real-world treatment of patients with psoriasis, use of brodalumab is associated with improved objective symptoms and satisfaction, according to a study.

The study included 75 patients, of whom 73 received brodalumab. Researchers assessed Psoriasis Area and Severity Index (PASI) scores, body surface area (BSA), and Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) domain scores at baseline and weeks 12 and 48 of treatment. Patient Global Assessment (PtGA) scores were also obtained at weeks 12 and 48.

There were marked reductions in both PASI scores and BSA at weeks 12 and 48 (p<0.0001 for all). Furthermore, the majority (90 percent) of patients felt the treatment was effective on the PtGA scale, while TSQM-9 domain scores showed significant improvements at weeks 12 and 48 (p<0.0001 for all).

A receiver operating characteristic curve analysis indicated that a PASI score of ≤2 was a suitable treatment goal for biologic treatment of psoriasis. However, some of the TSQM-9 domain scores did not improve in patients achieving the said goal.

There were no new safety signals reported.

The findings suggest that a PASI score of ≤2 as a goal for biologic treatment of psoriasis may be insufficient to clearly improve long-term patient satisfaction.